Mesa Laboratories, Inc.

As of June 5, 2024, Mesa Laboratories, Inc. is considered overvalued with a risky valuation grade, reflected in its high Price to Book Value of 3.55 and EV to EBITDA of 17.66, alongside significant losses and a year-to-date stock performance decline of 47.55%.

As of June 13, 2025, the technical trend has shifted to a moderately strong bearish stance, supported by a bearish MACD, daily moving average, and KST, while the RSI and Dow Theory show no clear signals.

As of June 5, 2024, Mesa Laboratories, Inc. is considered risky and overvalued due to its high Price to Book Value of 3.55, an EV to EBIT ratio of 44.16, negative Return on Equity of -2.97%, and a year-to-date stock return of -25.75%, significantly underperforming the S&P 500.

As of March 2022, the management team of Mesa Laboratories, Inc. includes Dr. John Sullivan (Chairman), Mr. Gary Owens (President and CEO), and several independent directors: Ms. Shannon Hall, Ms. Jennifer Alltoft, Mr. Evan Guillemin, Mr. David Kelly, and Mr. John Schmieder. They oversee the company's strategic direction and operations.

Mesa Laboratories, Inc. designs and manufactures quality control products for the Pharmaceuticals & Biotechnology industry, with a market cap of approximately $505.88 million. As of March 2025, the company reported net sales of $62 million and a net loss of $7 million.

As of Jun 18, Mesa Laboratories, Inc. has a market capitalization of 505.88 million and reported net sales of 240.97 million with a net profit of -1.97 million over the latest four quarters. Shareholder's funds are 159.83 million, and total assets amount to 433.35 million.